Application of praziquantel in preparing medicines for resisting Japanese schistosomiasis liver fibrosis

Abstract

The invention provides an application of praziquantel in preparing medicines for resisting Japanese schistosomiasis liver fibrosis. After carrying out disinfestation treatment on mice infected with schistosoma japonica, fibrosis resistant treatment is carried out by continuously applying the praziquantel so as to ensure that the liver fibrosis level is obviously improved, the serum glutamic pyruvic transaminase level is obviously reduced, and the splenomegaly signs of schistosomiasis are also obviously improved.

Description

1. Technical field [0001] The invention belongs to the field of medicine and provides praziquantel (2-cyclohexylformyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-α]isoquinoline- 4-keto, Praziquantel, PZQ) purposes in the preparation anti-Schistosomiasis japonicum hepatic fibrosis medicine. 2. Background technology [0002] Prior Art: Anti-hepatic fibrosis drugs are currently a research hotspot. So far, the drugs developed for liver fibrosis are not ideal in clinical application. For example, IFN-γ, which has anti-fibrosis effect, has relatively large side effects and is expensive; some receptor blockers, such as TGF-β, are affected. Body blockers, PDGF receptor blockers, etc., are still in the stage of animal experiments, have not been used in clinical practice, and their safety cannot be verified; , compound bovine fetal liver extract, etc., there may be large differences in individual treatment effects, and the active ingredients, anti-fibrosis mechanism, and toxic and side...

AI Technical Summary

Problems solved by technology

However, the use of praziquantel as an anti-schistosomiasis hepatic fibrosis drug has not been reported yet.

Images